Mayu Yunokawa

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

Kenji Tamura, Hiroaki Kurihara, Kan Yonemori et al. · Journal of Nuclear Medicine · 2013 · 295 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Benoît You, Mayu Yunokawa · The Lancet · 2023 · 209 citations

Medicine, Oncology, Pharmacology +12

Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

Yuko Tanabe, Kenji Hashimoto, Chikako Shimizu et al. · International Journal of Clinical Oncology · 2011 · 161 citations

Medicine, Oncology, Pharmacology +16